Serological test results in isolated colonic CD and UC
| Author/ref | Year | Study design | N (isolated colonic CD) | ASCA IgA (n/%) | ASCA IgG (n/%) | ASCA (IgG or IgA) (n/%) | pANCA (n/%) | ompC (n/%) | GP2 | UC results in same study | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Duerr et al113 | 1991 | Prospective | 18 | – | – | – | 5/18 (28%) | – | – | pANCA 34/40 (85%) | pANCA+ in isolated colonic CD not significant commoner than diarrhoea, predominantly IBS (4/27 15%) |
| Cambridge et al114 | 1992 | Stored sera IBD and healthy controls | 18 | – | – | – | 1/18 (6%) | – | – | pANCA 27/50 (54%) | pANCA+ in 4/32 CD with small bowel involvement |
| Joossens et al115 | 2002 | Prospective follow-up of 97 patients with initial diagnosis of indeterminate colitis | 17 | NA | NA | 10/17 (59%) | 6/17 (35%) | – | – | ASCA+ in 3/14 (21%) pANCA+ in 8/14 (57%) | All patients initially indeterminate |
| Lawrance et al116 | 2004 | Prospective Caucasian and Chinese | 35 | 6/35 (18%) | 9/35 (26%) | NA | NA | – | – | ASCA IgA 6/100 ASCA IgG 11/100 | ASCA less likely positive in isolated colonic CD than CD with ileal involvement |
| Annese et al117 | 2004 | Prospective | 61 | NA | NA | 25/61 (41%) | – | – | – | ASCA 32/197 (16%) | ASCA in CD overall 51% |
| Ferrante et al118 | 2007 | Prospective study IBD plus non-IBD and healthy controls | 70 | NA | 6% | NA | 21% | 3.5% | – | ASCA IgG 9.6% pANCA 37% | All antimicrobial abs lower titre in isolated colonic CD than other CD |
| Vind et al119 | 2008 | Prospective cohort | 60 | NA | NA | 5/60 (8%) | 15/60 (25%) | – | – | ASCA 14% pANCA 55% | ASCA CD overall 22% |
| Lakatos et al120 | 2009 | Cohort | 143 | NA | NA | NA | NA | – | – | ASCA (either IgA or IgG)+/pANCA– combination in 9% UC | ASCA (either IgA or IgG)+/pANCA– combination in 52% isolated colonic CD |
| Bogdanos et al121 | 2012 | Prospective paediatric | 32 | NA | NA | 5/32 (16%) | – | – | 2/32 (6.2%) | GP2 9/102 (8.8%) ASCA 7/102 (7%) | GP2 ab (IgG or IgA) in 49/137 (35.8%) other (non-L2) CD ASCA 55/137 (40.1%) other (non-L2) CD |
| Bertin et al122 | 2013 | Prospective recruited at colonoscopy | 67 | NA | NA | 21/67 (31%) | – | 15/67 (22%) | – | ompC 2/35 (6%) ASCA 5/35 (14%) | Colon mucosal culture supernatant ab measures discriminated better between L2 CD and UC |
| Elkadri et al109 | 2013 | Prospective cohort adults and children | 55 | NA | NA | NA but OR 0.25 (0.12–0.51; p=0.0002) for association with isolated colonic disease vs other sites | NA but OR 2.27 (1.50–4.92; p<0.03 for association with isolated colonic disease | 42.7% all CD, isolated CD NA | – | ASCA (either IgA or IgG) in 12.1% UC; 62.9% CD; pANCA in 55.6% UC, 14.3% CD; anti-ompC in 28.0% UC, 42.7% CD | ASCA positivity less common in isolated colonic CD than other sites |
CD, Crohn's disease; ASCA, anti-Saccharomyces cerevisiae; NA, not applicable; pANCA, perinuclear antineutrophil cytoplasmic antibodies.